Unknown

Dataset Information

0

Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments.


ABSTRACT: Diabetic peripheral neuropathy (DPN) occurs in up to half of individuals with type 1 or type 2 diabetes. DPN results from the distal-to-proximal loss of peripheral nerve function, leading to physical disability and sometimes pain, with the consequent lowering of quality of life. Early diagnosis improves clinical outcomes, but many patients still develop neuropathy. Hyperglycaemia is a risk factor and glycaemic control prevents DPN development in type 1 diabetes. However, glycaemic control has modest or no benefit in individuals with type 2 diabetes, probably because they usually have comorbidities. Among them, the metabolic syndrome is a major risk factor for DPN. The pathophysiology of DPN is complex, but mechanisms converge on a unifying theme of bioenergetic failure in the peripheral nerves due to their unique anatomy. Current clinical management focuses on controlling diabetes, the metabolic syndrome, and pain, but remains suboptimal for most patients. Thus, research is ongoing to improve early diagnosis and prognosis, to identify molecular mechanisms that could lead to therapeutic targets, and to investigate lifestyle interventions to improve clinical outcomes.

SUBMITTER: Elafros MA 

PROVIDER: S-EPMC10112836 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments.

Elafros Melissa A MA   Andersen Henning H   Bennett David L DL   Savelieff Masha G MG   Viswanathan Vijay V   Callaghan Brian C BC   Feldman Eva L EL  

The Lancet. Neurology 20221001 10


Diabetic peripheral neuropathy (DPN) occurs in up to half of individuals with type 1 or type 2 diabetes. DPN results from the distal-to-proximal loss of peripheral nerve function, leading to physical disability and sometimes pain, with the consequent lowering of quality of life. Early diagnosis improves clinical outcomes, but many patients still develop neuropathy. Hyperglycaemia is a risk factor and glycaemic control prevents DPN development in type 1 diabetes. However, glycaemic control has mo  ...[more]

Similar Datasets

| S-EPMC10936109 | biostudies-literature
| S-EPMC10215986 | biostudies-literature
| S-EPMC3581201 | biostudies-literature
| S-EPMC10784801 | biostudies-literature
| S-EPMC5084622 | biostudies-literature
| S-EPMC7990935 | biostudies-literature
| S-EPMC9360478 | biostudies-literature
| S-EPMC5885181 | biostudies-literature
| S-EPMC2713635 | biostudies-literature
| S-EPMC9410148 | biostudies-literature